The role of metabolites in morphine analgesic effects

Abstract
Morphine is metabolized into two main metabolites, morphine-3-glucuronide and morphine-6-glucuronide. Morphine-6-glucuronide is a potent analgesic that is responsible for up to 97% of the analgesic effect. Morphine-3-glucuronide does not bind to opioid receptors and is devoid of any analgesic effect. However, it activates the Toll-like 4 receptors initiating neurogenic inflammation in the central nervous system. This, in turn, is responsible for anti–analgesic and hyperalgesic effects. There are a number of strategies on how to inhibit this pronociceptive effect and finally improve morphine analgesia.

Key words: pain, morphine metabolism, morphine-3-glucuronide, morphine-6-glucuronide, opioid receptors, analgesia, Toll-like 4 receptors

Introduction
Morphine as a drug isolated from opium is known in medicine for more than 200 years [1]. It is one of the most important and efficacious drugs used in pain treatment [2]. Slightly less well known is morphine’s effect on breathlessness and diarrhoea. Morphine experienced its renaissance at the end of the past century when it became evident that it is, despite its shortcomings, a cheap, good and powerful drug for the treatment of cancer-related pain [3]. Earlier morphine was considered to be unable to reach sufficient concentrations in blood because of the first pass metabolism in the liver [4]. Tolerance and opioid-induced hyperalgesia [5] belong to the most feared features of morphine. The fact that morphine is metabolized to glucuronides is known for several decades [6]. However, the exact role of these metabolites in the morphine analgesia is still a matter of debate and uncertainty. The role of metabolites and strategies on how to influence their activity will be discussed in this paper.

Pharmacology
Morphine is a hydrophilic drug and it can be administered orally, subcutaneously, intravenously, intramuscularly, intrathecally, epidurally, and rectally. Additionally, nebulized morphine can be used in the treatment of breathlessness [7]. After parenteral administration, it penetrates easily to the central compartment and especially to the well–perfused organs. It is eliminated from the central compartment with the T½ of 1.4–3.4 hours. Similar elimination T½ is observed after oral, subcutaneous, intravenous, and intramuscular administration [8, 9].

After oral administration morphine is fully absorbed from the gut and transported to the liver, where it undergoes rapid metabolism to two main metabolites: morphine-3-glucuronide (M3G) and morphine-6-glu-
curonide (M6G) [10]. The enzyme responsible for this, UGT2D7 metabolizes morphine in a constant proportion of M6G/M3G 1:9 [10]. Brain and other tissues may have variant enzymes, so we only assume that the proportion known from the liver metabolism is the same in all other tissues [11]. A small quantity of morphine is metabolised in the liver to normorphine by a CYP3A4 enzyme [12]. However, normorphine is a much weaker analgesic than morphine and does not appear to be toxic [13]. The overall bioavailability of morphine is variable and is approximately 20–30% [14]. The drug with this profile would never be licensed to be used in the 21st century. The unpredictability of the bioavailability is reflected by the individual doses of morphine and the need of the dose titration until analgesia is achieved. Approximately 10% of the original dose is excreted unchanged with urine. The rest is excreted by the kidney as glucuronides and as other minor metabolites with the bile [15].

**Diffusion of morphine and its metabolites through the blood-brain barrier**

Morphine, as a hydrophilic drug, penetrates with difficulty through the blood-brain barrier in a paracellular mode [10]. This means, that the drug needs to accumulate considerably at the blood side to create enough gradient. Once in, some of the drug is actively pumped out by a P-glycoprotein [16]. Inhibition of this enzyme by a number of drugs and naturally occurring substances may increase morphine toxicity [17]. More hydrophilic metabolites cross the blood-brain barrier with even greater difficulty. However, M6G is probably primarily actively transported into the brain by the endothelial Oatp2 protein [18, 19]. This may explain M6G analgesic potency when given parenterally in the treatment of postoperative pain which is comparable to morphine itself [20]. Anyway, in the liquor part of the M6G originates from liver metabolism and part is synthesized de novo in the brain [21]. Brain UGT2B7 glucuronidase appears in a number of variants [22]. One of these variants occurs in the sickle cell disease and it causes decreased glucuronidation of morphine [23]. It explains why morphine is inefficacious in the pain crisis during this disease [24]. Naloxone, which crosses the blood-brain barrier abolishes fully morphine analgesia, while the naloxone derivatives which do not cross the blood-brain barrier show no effect.

M6G administered systemically in humans has an analgesic potency roughly equal to those of morphine [20]. However, the same drug administered intracerebrally in rats is 100 times more potent than morphine [25]. In the first hours, systemically administered morphine is more potent compared to systemically administered M6G. This is probably due to slow diffusion through the blood–brain barrier. The cycle morphine-diffusion-metabolism in the brain to M6G is faster than the diffusion of M6G. It is estimated that 91–97% of the analgesic effect of morphine is due to M6G [26] and morphine can be seen as a pro–drug. However, in the case of renal insufficiency M6G will accumulate and can be toxic or even lethal [27, 28]. Renal function declines with age and at the age of 90 years, it is only half of the original value in children [29]. This is also the reason why children and adolescents need higher morphine doses in comparison to the geriatric population.

**The role of morphine-3-glucuronide in pain treatment**

M3G does not bind to any opioid receptor and is devoid of any analgesic effect [30]. In a very high dose, 30 mg IV, administered to healthy subjects it did not show any pharmacological effect [31]. It does not cross the blood–brain barrier. Plasma concentrations of M3G increase in renal insufficiency [32]. And yet, M3G for many years has been suspected to act antagonistically to morphine, and to induce opioid-induced hyperalgesia [33, 34]. A long search revealed its binding to the Toll-Like 4 receptors (TLR4) on the microglial cells and on macrophages [35–37]. TLR4 is one of many Toll-like receptors that organize an innate immune response reacting to foreign and endogenous harmful impulses, most often bacterial lipopolysaccharides (LPS) [38]. TLR4 is the key factor for all processes that for many years were collectively named neurogenic inflammation [39, 40]. These receptors bind a wide range of drugs and are not stereoselective [41]. Recently, TLR4 were considered to be crucial for understanding the emergence of many diseases, such as neurodegenerative, autoimmune, infectious and/or neoplastic diseases [42–44], as well as chronic pain [45]. M3G activates TLR4 as comparably to the bacterial-derived lipopolysaccharides (LPS) [46]. Activation of TLR4 increases production of inflammatory cytokines: TNF-Α, IL-1β, IL-6 and IFN-γ45 and prostaglandins [47]. TLR4 explain different phenomena such as tolerance, hyperalgesia, pruritus, and cough [47, 48].

**Strategies to overcome Toll-like 4 receptors activation**

TLR4 inhibition with normally inactive on the opioid receptors (+)-naloxone, results in the abolition of
morphine tolerance [47]. Moreover, treatment with (+)-naloxone greatly improved morphine analgesia in a rat nerve constrictor model [49, 50]. It is not surprising that TLR4 has become an important target for new drugs [51]. Glucocorticoids have been shown to block certain genes involved in the activation of TLR4 [52]. Tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRI) are known for their role in inhibition of Toll-like receptors and may be used to improve analgesic effects of opioids [53].

Summary

Morphine metabolism to two main metabolites M3G and M6G has been known for decades. The implications of this metabolism for pain treatment became apparent only recently. Morphine, in fact, is a pro–drug which needs to be glucurononated to M6G and act in the spinal cord and brain. Part of this process starts already in the liver, during the first pass metabolism. Morphine crosses the blood-brain barrier easier than M6G but M6G can be actively transported by Oatp2 and by de novo synthesis of M6G from morphine in the brain. Those mechanisms together make it possible that M6 is the main analgesic responsible for up to 97% of morphine analgesic effect.

The second metabolite, M3G usually seen as inactive and less important is the agonist to the TLR4 receptor and responsible for morphine N-demethylation in human liver microsomes. Xenobiotica. 2003; 33(8): 841–854, doi: 10.1080/0049825031000121608, indexed in Pubmed: 12936704.

References